National Cancer Institute (NCI): Communicable Diseases trials

The registry lists 14 Communicable Diseases studies with National Cancer Institute (NCI) as lead sponsor. 0 are open to participants now and 0 have results posted.

Phase 1 8Phase 2 1No phase 5(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid TumorsCompletedNCT02143401Phase 1
• Erlotinib Hydrochloride in Treating Non-Small Cell Lung Cancer That is Metastatic or Cannot be Removed by Surgery in Patients With HIV InfectionTerminatedNCT02134886Phase 1
• HIV Infection and Tobacco Use Among Injection Drug Users in Baltimore, Maryland: A Pilot Study of BiomarkersCompletedNCT00491335
• HLA and KIR Associations With Infectious Viral Agents in an HIV Cohort of Women (WIHS)CompletedNCT00339430
• Voriconazole With or Without Interferon Gamma in Treating Patients With Aspergillosis or Other Fungal InfectionsCompletedNCT00059878Phase 2
• Capravirine to Treat Children With HIV InfectionCompletedNCT00006519Phase 1
• Combination Drug Treatment of Pediatric HIV InfectionCompletedNCT00001818Phase 1
• Clinical, Laboratory and Epidemiologic Pilot Studies of Individuals at High Risk for Viral-Associated CancersCompletedNCT00001560
• Assessment of Attentional Functioning in Children With HIV-1 InfectionCompletedNCT00001497
• The Effect of Oral Candidiasis on the Speech Production, Feeding Skills, and Self-Concept of Children and Adolescents With Symptomatic HIV InfectionCompletedNCT00001448
• Phase I Study to Evaluate the Safety and Immunogenicity of HIV-1 Immunogen in Children With HIV-1 InfectionCompletedNCT00001445Phase 1
• A Phase I /II Study of the Protease Inhibitor Indinavir (MK-0639) in Children With HIV InfectionCompletedNCT00001443Phase 1
• Phase I Protocol for the Evaluation of the Safety and Immunogenicity of Vaccination With Synthetic HIV Envelope Peptides in Patients With Early Human Immunodeficiency Virus InfectionCompletedNCT00001386Phase 1
• A Phase I Study to Evaluate the Safety and Toxicity of the Combination of Zidovudine and 2',3'-Dideoxyinosine (Didanosine) in Children With HIV InfectionCompletedNCT00000652Phase 1